Villers-lès-Nancy, 5 July 2020 – 6:00 p.m. (CET)
COMMUNIQUE DE PRESSE
RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED
TO THE ORDINARY ANNUAL SHAREHOLDERS’ MEETING
OF 29 JUNE 2021
Number of shares comprising the share capital: 15,174,125
Number of shares with voting rights: 15,019,318
Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 12,635,083
Despite the continuing health crisis linked to the COVID-19 epidemic, in light of the number of persons normally present at the Company’s general meetings and the characteristics of the meeting rooms of the Company’s registered office on the one hand, and the goal of promoting dialogue with shareholders on the other hand, the Board of Directors wanted to provide for the possibility of permitting physical in-person attendance of shareholders at the Company’s general meeting.
The Ordinary Annual General Meeting was held on Tuesday, 29 June 2021 at 5:00 p.m. at the Company’s headquarters and approved the separate parent company and consolidated financial statements for the 2020 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:
| Resolutions | Results of the votes |
| Approval of the annual financial statements for the fiscal year ended 31 December 2020 | Resolution adopted by:
|
| Discharge of Directors and discharge of the Statutory Auditors for the performance of their engagement | Resolution adopted by:
|
| Approval of the consolidated financial statements for the period ended 31 December 2020 | Resolution adopted by:
|
| Appropriation of earnings, setting the dividend | Resolution adopted by:
|
|
Resolution adopted by (*):
|
| Renewal of Ms. Marie-Louise LIGER’ s term of office as Director | Resolution adopted by:
|
| Renewal of Mr. Dominique PAUTRAT’s term of office as Director |
Resolution adopted by:
|
| Renewal of Mr. Denis SUPPLISSON’s term of office as Director | Resolution adopted by:
|
| Approval of information on the compensation of each corporate officer (Article L. 22-10-9 of the French Commercial Code) | Resolution adopted by:
|
| Approval of the components of compensation paid in 2020 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors | Resolution adopted by:
|
| Approval of the components of compensation paid in 2020 to Mr. Dominique PAUTRAT, Managing Director | Resolution adopted by:
|
| Approval of the components of compensation paid in 2020 to Mr. Denis SUPPLISSON, Deputy Managing Director | Resolution adopted by:
|
| Approval of the components of compensation paid in 2020 to Mr. Grégoire de ROTALIER, Deputy Managing Director | Resolution adopted by:
|
| Approval of the compensation policy for the Chairman of the Board of Directors for 2021 | Resolution adopted by:
|
| Approval of the compensation policy for the Chief Executive Officer for 2021 | Resolution adopted by:
|
| Approval of the compensation policy for the Deputy Managing Directors for 2021 | Resolution adopted by:
|
| Approval of the compensation policy for non-executive corporate officers for 2021 | Resolution adopted by:
|
| Setting total annual compensation for Directors for 2021 | Resolution adopted by:
|
| Authorisation by the Company to repurchase its own shares | Resolution adopted by:
|
| Powers for formalities | Resolution adopted by:
|
(*) After deduction of excluded voting rights
Financial calendar:
- Publication of H1 2021 Revenue: 4 August 2021.
- Publication of H1 2021 Results: 24 September 2021.
About Pharmagest Group:
With more than 1,100 employees acting as “Citizens in the Service of Health and Well-Being”, Pharmagest Group is the leading provider of IT solutions for the healthcare sector in Europe through innovative solutions and services for healthcare professionals guaranteeing the efficiency of the healthcare system and improving the patient care pathway.
As a key contributor to the quality of healthcare and coordination between office-based private practice and hospitals, Pharmagest Group is present in France, Italy, Belgium, Luxembourg and the United Kingdom where it is developing the leading healthcare platform and a single ecosystem for France and Europe bringing the best of technology to the service of people.
Listed on Euronext Paris™ – Compartment B
Indexes: MSCI GLOBAL SMALL CAP – GAÏA Index 2020 – CAC® SMALL and CAC® All-Tradable
Included under the European Rising Tech label.
Eligible for the “long-only” Deferred Settlement Service (“Service à Réglement Différé” – SRD) and equity savings accounts invested in small and mid caps (PEA-PME)
ISIN: FR 0012882389 – Reuters: PHA.PA – Bloomberg: PMGI FP
For all the latest news go to www.pharmagest.com
Follow Pharmagest on Twitter: @Pharmagest, LinkedIn and Facebook
CONTACTS
Analyst and Investor Relations:
Chief Administrative and Financial Officer: Jean-Yves SAMSON
Tel. +33 (0)3 83 15 90 67 – jean-yves.samson@lacooperativewelcoop.com
Media Relations:
FIN’EXTENSO – Isabelle APRILE
Tel. +33 (0)1 39 97 61 22 – i.aprile@finextenso.fr
